Gland Pharma Limited (NSE: GLAND) reported Revenue from Operations of ₹938.28 Crore down from ₹1,063.32 Crore year on year, a decline of 11.8%. Consolidated Net Profit of ₹231.94 Crore, slumped 15% from ₹273 Crore in the same quarter of the previous year. The Earnings per Share is ₹14.08 for this quarter.
Gland Pharma Limited Q3 FY23; Net Profit Down To 232 Crore
Related Post
- NLC India Ltd Q2FY25; 10% fall in Profits
NLC India is engaged in the business of mining of lignite and generation of power…
-
NHPC Ltd Q2FY25; 37% fall in Profits
NHPC, a Mini Ratna category I public sector utility, is Government of India’s flagship hydroelectric…
-
Ashok Leyland Ltd Q2FY25; 35% rise in Profits
Ashok Leyland is the flagship Company of the Hinduja group, having a long-standing presence in…